kabutan

Heartseed surges to daily limit up following positive phase 1/2 trial results for allogeneic iPS cell-derived cardiac spheroids

Tue Jun 2, 2026 9:28 am JST Catalyst

Shares of Heartseed Inc. <219A> surged by their daily limit to touch 1,705 yen on Tuesday, fueled by positive Phase 1/2 trial results for its severe heart failure treatment. After the close on Monday, the biotech firm announced that its LAPiS trial of HS-001?an allogeneic iPS cell-derived cardiac spheroid?met its primary safety endpoint with no issues that would disrupt regulatory plans. Furthermore, secondary endpoints demonstrated efficacy across multiple metrics, providing strong support for an approval filing. Backed by these outcomes, Heartseed aims to apply for manufacturing and marketing approval by the end of 2026.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles